Pages that link to "Q54118572"

The following pages link to Contractile properties of human prostate adenomas and the development of infravesical obstruction. (Q54118572):

Displaying 26 items.

• Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression (Q27027373) (← links)
• The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data (Q30945262) (← links)
• The Residual Nonadrenergic Contractile Response to Nerve Stimulation of the Mouse Prostate Is Mediated by Acetylcholine but Not ATP in a Comparison with the Mouse Vas Deferens (Q34257555) (← links)
• Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). (Q35089850) (← links)
• Structural modifications of the prostate in hypoxia, oxidative stress, and chronic ischemia (Q35164802) (← links)
• Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate (Q35545711) (← links)
• Benign prostatic hyperplasia: an insight into current investigational medical therapies (Q36300022) (← links)
• Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options (Q36329271) (← links)
• Therapeutic options in the treatment of benign prostatic hyperplasia (Q37423744) (← links)
• A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia (Q38533290) (← links)
• A possible role of decreased relaxation mediated by β‐adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia (Q41909908) (← links)
• Comparison of alpha1Adrenoceptors in the Prostate Capsule of Men with Symptomatic and Asymptomatic Benign Prostatic Hyperplasia (Q44277317) (← links)
• Determination of Norepinephrine Levels in the Adult Human Prostate (Q44746103) (← links)
• Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. (Q44779375) (← links)
• Non-Adrenergic, Tamsulosin-Insensitive Smooth Muscle Contraction is Sufficient to Replace α1 -Adrenergic Tension in the Human Prostate (Q47997829) (← links)
• The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. (Q53628573) (← links)
• Characterization of 1,4, Dihydropyridine Calcium Channel Binding Sites in the Human Prostate (Q67674955) (← links)
• Norepinephrine contents of human prostatic hyperplasia: differences between pathological subtypes (Q71342076) (← links)
• Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis (Q71635976) (← links)
• Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: A pilot study (Q71643339) (← links)
• G-proteins in alpha 1-adrenoceptor mediated prostatic smooth muscle contraction (Q71661903) (← links)
• Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates (Q73280021) (← links)
• Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial (Q73807682) (← links)
• Functional property, norepinephrine content and morphometric findings in human hyperplastic prostate (Q73868509) (← links)
• Pathophysiology of benign prostatic hyperplasia in the aging male population (Q80298245) (← links)
• Pathophysiology of lower urinary tract symptoms in the aging male population (Q80298289) (← links)